Roche’s Rituxan Gets FDA Nod as Maintenance Therapy for Blood Cancer

Drug Industry Daily
A A
FDA has cleared Roche’s Rituxan for first-line maintenance use in patients with advanced follicular lymphoma (FL) who responded to initial treatment with Rituxan and chemotherapy.

To View This Article:

Login

Subscribe To Drug Industry Daily